# Scenario 001 Medical Plausibility And Safety Review

## Purpose

Review whether Scenario 001 is medically plausible enough for prototype evaluation and portfolio use.

This is a bounded review of a synthetic protocol scenario. It is not clinical advice, protocol approval, IRB review, regulatory review, or a replacement for clinical/statistical expert review.

## Reviewed Materials

Local project artifacts:

- `prototype/inputs/scenario_001.json`
- `experiments/scenario_001_type2_diabetes.md`
- `prototype/runs/scenario_001_run_001/final_report.md`
- `prototype/runs/scenario_001_run_001/top_trial_comparison.md`
- `prototype/runs/scenario_001_run_001/top_trial_interpretation_notes.md`
- `prototype/runs/scenario_001_run_001/data_readiness_table.md`

External reference checks:

- DailyMed Ozempic label, updated June 1, 2026: GLP-1 receptor agonist indication for adults with type 2 diabetes, plus warnings for pancreatitis, hypoglycemia with insulin/secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, gallbladder disease, pregnancy planning, and thyroid C-cell tumor risk. Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- ClinicalTrials.gov record `NCT01596504`, retrieved and normalized in `sources_ranked.json`.
- ClinicalTrials.gov record `NCT01117350`, retrieved and normalized in `sources_ranked.json`.

## Overall Assessment

Status:

- plausible for a synthetic prototype scenario.

Rationale:

- Adult type 2 diabetes with GLP-1 receptor agonist therapy is a medically realistic scenario area.
- HbA1c, body weight, fasting plasma glucose, renal labs, pregnancy testing, adverse events, concomitant medications, informed consent documentation, and visit follow-up are plausible protocol data elements.
- Public registry records include similar type 2 diabetes GLP-1-related trials with explicit HbA1c eligibility ranges, comparator/background therapy details, and safety exclusions.

Important limitation:

- The current scenario is suitable for evaluating an agent workflow, not for validating a real clinical protocol.

## Plausibility Findings

### 1. Disease And Intervention

Assessment:

- plausible.

Reasoning:

- The scenario targets adults with type 2 diabetes and inadequate glycemic control.
- A GLP-1 receptor agonist add-on framing is broadly plausible because GLP-1 receptor agonists are used in type 2 diabetes care.
- The scenario correctly avoids type 1 diabetes by listing type 1 diabetes as an exclusion criterion.

Remaining issue:

- The phrase "GLP-1 receptor agonist add-on therapy" is still too broad for an actual protocol. A real protocol would need a specific investigational or approved agent, dose, route, titration schedule, comparator, and background therapy rules.

### 2. Primary Endpoint

Assessment:

- plausible but needs justification.

Reasoning:

- Change in HbA1c from baseline is a standard glycemic endpoint concept in type 2 diabetes studies.
- Week 24 is plausible as a medium-duration glycemic endpoint, and one retrieved comparison candidate (`NCT01117350`) includes week 24 HbA1c target-related assessment.

Remaining issue:

- The top-ranked Phase II candidate (`NCT01596504`) uses a short-term pharmacodynamic glucose AUC endpoint at Day 56, not week 24 HbA1c change. This means the scenario endpoint is plausible but not directly proven by the highest-ranked comparison trial.

Recommended improvement:

- Add a short rationale for why week 24 HbA1c change is selected over shorter pharmacodynamic endpoints.
- Keep HbA1c target achievement as a secondary endpoint if clinically appropriate.

### 3. Eligibility Criteria

Assessment:

- structurally plausible but currently incomplete.

Strengths:

- Adult age range is specified.
- Type 2 diabetes diagnosis is required.
- Pregnancy/breastfeeding, type 1 diabetes, pancreatitis history, severe renal impairment, and other trial participation are listed as exclusions.
- Informed consent ability is included.

Key gaps:

- HbA1c eligibility is not numeric.
- Severe renal impairment is not operationalized.
- Prior GLP-1 receptor agonist exposure is not defined.
- Current injectable therapy exclusion may conflict with recruitment feasibility or background therapy strategy.
- Thyroid C-cell tumor risk/MTC/MEN2-related exclusion is not currently represented.
- Severe gastrointestinal disease/gastroparesis is not currently represented.

Recommended improvement:

- Add numeric HbA1c range.
- Add eGFR or creatinine-clearance threshold.
- Define prior and current GLP-1 receptor agonist exposure.
- Clarify whether insulin-treated patients are excluded, allowed, or stratified.
- Add MTC/MEN2 and severe gastrointestinal disease screening considerations for review by clinical experts.

### 4. Safety Monitoring

Assessment:

- safety-relevant concepts are present, but the monitoring plan is incomplete.

Reasoning:

- The scenario includes pancreatitis history, pregnancy/breastfeeding, renal function labs, pregnancy testing, adverse events, and concomitant medications.
- DailyMed Ozempic labeling highlights safety topics that are directly relevant to protocol review: pancreatitis, hypoglycemia risk with insulin or insulin secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal reactions, gallbladder disease, pregnancy planning, and thyroid C-cell tumor risk.

Key gaps:

- No adverse event capture workflow is defined.
- No safety lab schedule is defined.
- No stopping rules or escalation rules are defined.
- No responsible reviewer role is defined.
- No serious adverse event reporting workflow is defined.

Recommended improvement:

- Add an adverse event collection and review workflow.
- Add safety lab schedule and trigger thresholds.
- Add SAE escalation and reporting responsibility.
- Add medication reconciliation workflow for insulin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and prior GLP-1 exposure.

### 5. Hospital Data-Readiness

Assessment:

- plausible and now aligned with hospital/research operations.

Strengths:

- Routine hospital-system data are separated from mixed or research-only/manual data.
- Informed consent documentation is explicitly mapped as research-only/manual documentation.
- Adverse events are correctly treated as high-risk research-specific capture plus clinical note review.

Remaining issue:

- The mapping is generic. It does not verify any real hospital EMR/HIS configuration.

Recommended improvement:

- In the proposal, describe this as a planning-level data-readiness map, not as actual system integration.
- Add a future integration boundary: no real patient data, no direct EMR access in MVP.

### 6. Recruitment Feasibility

Assessment:

- plausible as a concern, not yet supported as an assumption.

Reasoning:

- A single-center hospital-based recruitment assumption of 80 participants over 6 months may be possible in some settings but needs screening-pool evidence.
- Excluding all current injectable diabetes therapy may reduce the eligible pool.
- Retrieved trials show that some GLP-1-related type 2 diabetes studies include insulin or specific background therapy rules, so the draft exclusion strategy needs justification.

Recommended improvement:

- Add a screening funnel estimate.
- Add historical diabetes clinic volume or registry-screening assumptions.
- Clarify whether injectable therapy exclusion is clinically necessary.

## Safety Boundary Review

No unsafe claim found in current project outputs:

- no protocol approval claim,
- no regulatory compliance guarantee,
- no patient-specific treatment recommendation,
- no recruitment success guarantee,
- no real patient data access assumption.

Required continuing boundary:

- Every output should keep stating that the workflow prepares expert review and does not replace PI, CRC, IRB/regulatory, sponsor, statistician, or medical data-team review.

## Decision

Scenario 001 is acceptable as the first synthetic prototype scenario.

It is medically plausible enough for portfolio and workflow demonstration if the following caveats are preserved:

- not a real protocol,
- not a treatment recommendation,
- not regulatory or IRB review,
- no real patient data,
- clinical expert validation required.

## Next Recommended Action

Update the concept note and proposal narrative to reflect the current evidence-backed workflow:

- protocol completeness checking,
- similar-trial retrieval and ranking,
- top-trial interpretation,
- hospital data-readiness mapping,
- safety boundary checking.
